Page number 125

63 Investor presentation Full year 2022 Patient access to anti-obesity me the US and IO The~40 million people having access to Wegovy ® is nearly the number of people with diabetes in the US (~50 million) ~110m Obesity prevalence in US adults 1 ~60m Commercial Channel • ~80% formulary access • ~50% of employers opt-in ~30m People with commercial coverage ~10m Medicaid 2 Note: Obesity is defined as BMI > 30. 1 Prevalence: Adult obesity facts. Centers for Disease Control and Prevention, https://www.cdc.gov/obesity/data/adult.html; US Cens 2 Also includes DoD and government employees

Page number 126

Novo Nordisk ® edications is improving in both Restricted reimbursement for Saxenda ® is progressing EXAMPLES BMI > 30 with one co-morbidity BMI ~ > 2 3 4 5 0 million ~250 million With pre-diabetes and risk of CV ~60% coverage by private insurance, 20% of which includes restricted/unrestricted coverage ~75 million Saxenda ® reimbursed in April 2020 in selected patient groups sus Bureau. QuickFacts: United States. https://www.census.gov/quickfacts/fact/table/US#viewtop. Accessed Mar, 2021.;

    ...